Document:

<PAGE>
                                                                   Exhibit 10.17

    CONFIDENTIAL TREATMENT REQUESTED: CONFIDENTIAL PORTIONS OF THIS DOCUMENT
     HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.

                                LICENSE AGREEMENT
                                -----------------

         This Agreement is made effective as of the 15th day of may, 1995, by
and between Wisconsin Alumni Research Foundation (hereinafter called "WARF"),
a nonstock, nonprofit Wisconsin corporation and Nomos Corporation (hereinafter
called "Nomos"), a corporation organized and existing under the laws of
Delaware;

         WHEREAS, WARF owns certain inventions that are described in the
"Licensed Patents" defined below, and WARF is willing to grant a license to
Nomos under any one or all of the Licensed Patents and Nomos desires a license
under all of them;

         NOW, THEREFORE, in consideration of the mutual covenants and agreements
set forth below, the parties covenant and agree as follows:

         Section 1.        Definitions.

         For the purpose of this Agreement, the Appendix A definitions shall
apply.

         Section 2.        Grant.

                  A.       LICENSE.

                           (i)      MEDICAL IMAGING FIELD LICENSE.

         WARF hereby grants to Nomos: (1) a nonexclusive license, limited to the
Medical Imaging Field and the Licensed Territory, under the Licensed Patents to
make, use, offer to sell and sell Products; and (2) the right to grant
nonexclusive sublicenses under such license to purchasers, lessees and/or users
of Products of Nomos to use such Products purchased or leased from Nomos.

                           (ii)     ADD-ON DEVICE FIELD LICENSE.

         WARF hereby grants to Nomos: (1) an exclusive license, limited to the
Add-on Device Field and the Licensed Territory, under the Licensed Patents to
make, use, offer to sell and sell Products; and (2) the right to grant
nonexclusive sublicenses under such license to purchasers, lessees and/or users
of Products of Nomos to use such Products purchased or leased from Nomos. The
license granted under Section 2A(ii)(1) shall automatically convert to a
nonexclusive license three years after the date of this Agreement.

                  B.       LICENSE TO WARF.

         Licensee hereby grants WARF a nonexclusive, royalty-free, irrevocable,
paid-up, worldwide license under the Nomos Patents to make, use and sell any
product that employs or is in any way produced by the practice of an invention
claimed in the Nomos Patents or that would

<PAGE>

otherwise constitute infringement of any claims of the Nomos Patents. WARF shall
have the right to grant sublicenses to others with respect to such rights
provided that WARF also has granted such sublicensee a license under the
Licensed Patents.

         Section 3.        Consideration.

                  A.       LICENSE FEE.

         Nomos agrees to pay to WARF a license fee of $[* * *], with the first $
due by June 15, 1995 and the remaining $[* * *] due by August 31, 1995.

                  B.       COMPENSATION FOR PRIOR USAGE.

         Prior to the date of this Agreement, Nomos represents and warrants that
it sold a total of nine (9) Products in the Add-On-Device Field which would
require a royalty payment of $[* * *] in accordance with Section 3C if sold
pursuant to the terms of this Agreement. In consideration for this prior usage,
Nomos shall pay WARF this additional $[* * *] royalty amount, with the first $[*
* *] due by June 15, 1995 and the remaining $[* * *] due by August 31, 1995.
Subject to the receipt of such payment, WARF hereby releases Nomos and its
distributors and customers against any claims that WARF may have for use of the
Licensed Patents with respect to the nine (9) Products in the Add-On-Device
Field sold prior to the date of this Agreement. [* * *]

                  C.       ROYALTY.

                           (i)      In addition to the payments required by
Sections 3A and 3B, Nomos agrees to pay to WARF as "earned royalties" a royalty
equal to $[* * *] for each Product Unit sold or leased by Nomos in the Add-On
Device Field after the date of this Agreement. Such royalty rate shall be
reduced by [* * *] for any Product Units sold or leased by Nomos after the date
WARF grants a license to any other party under the Licensed Patents in the
Add-On Device Field and the Licensed Territory (which shall not occur before
three years after the date of this Agreement). In addition, Nomos shall pay WARF
an additional royalty of $[* * *] for each Verification Product Unit leased or
sold in the Add-On-Device Field. [* * *] Nomos agrees to keep the royalty rates,
license fee, compensation for prior usage and other commercial terms of this
Agreement confidential using reasonable procedures at least as stringent as
those Nomos uses to keep its own sensitive information confidential.

                           (ii)     In addition to the payments required by
Sections 3A and 3B, Nomos agrees to pay to WARF as "earned royalties" a royalty
equal to $[* * *] for each Product Unit sold or leased by Nomos outside of the
Add-On-Device Field after the date of this Agreement.

                           (iii)    A Product Unit is deemed sold or leased and
a royalty is deemed earned under this Agreement as of the earlier of the date
the Product Unit is actually sold and paid for, the date an invoice is sent by
Nomos, the date a lessee takes possession of a Product

--------------------
* * * Confidential material redacted and filed separately with the Commission.

                                      -2-
<PAGE>

Unit, or the date a Product Unit is otherwise transferred to a third party for
consideration (excluding transfers of Product Units to third parties solely for
research purposes if Nomos does not receive any monetary consideration with
respect to such transfer). If Nomos sells a Product Unit that is later returned
by the customer with Nomos repaying the customer the full consideration paid
therefor (excluding a restocking fee which may be retained by Nomos of up to
$[* * *] per Product Unit returned), then no royalty shall be charged with
respect to such Product Unit and, to the extent any royalty was previously paid
to WARF with respect to such Product Unit, the royalty shall be credited against
future royalties payable to WARF under this Agreement.

                           (iv)     WARF is exempt from paying income taxes
under U.S. law. Therefore, all payments due under this Agreement shall be made
without deduction for taxes, assessments, or other charges of any kind which may
be imposed on WARF by any government outside of the United States or any
political subdivision of such government with respect to any amounts payable to
WARF pursuant to this Agreement. All such taxes, assessments, or other charges
shall be assumed by Nomos.

                  D.       MINIMUM ROYALTY.

         Nomos further agrees to pay to WARF a minimum royalty of $[* * *] per
calendar year or part thereof during which this Agreement is in effect starting
in calendar year 1996, against which any earned royalty paid for the same
calendar year will be credited. The minimum royalty for a given year shall be
due at the time payments are due for the calendar quarter ending on December 31.
It is understood that the minimum royalties will apply on a calendar year basis,
and that sales of Products requiring the payment of earned royalties made during
a prior or subsequent calendar year shall have no effect on the annual minimum
royalty due WARF for any given calendar year.

                  E.       ACCOUNTING; PAYMENTS.

                           (i)      Amounts owing to WARF under Section 3C shall
be paid on a quarterly basis, with such amounts due and received by WARF on or
before the thirtieth day following the end of the calendar quarter ending on
March 31, June 30, September 30 or December 31 in which such amounts were
earned. The balance of any amounts which remain unpaid more than thirty (30)
days after they are due to WARF shall accrue interest until paid at the rate of
the lesser of one percent (1%) per month or the maximum amount allowed under
applicable law. However, in no event shall this interest provision be construed
as a grant of permission for any payment delays.

                           (ii)     Except as otherwise directed, all amounts
owing to WARF under this Agreement shall be paid in U.S. dollars to WARF at the
address provided in Section 16(a). All royalties owing with respect to Selling
Prices stated in currencies other than U.S. dollars

----------------------
* * * Confidential material redacted and filed separately with the Commission.

                                      -3-

<PAGE>

shall be converted at the rate shown in the Federal Reserve Noon Valuation -
Value of Foreign Currencies on the day preceding the payment.

                           (iii)    A full accounting showing how any amounts
owing to WARF under Section 3C have been calculated shall be submitted to WARF
on the date of each such payment. Such accounting shall be on a per-country and
model or tradename basis and shall be summarized on the form shown in Appendix C
of this Agreement. Such accounting shall also describe any returned Product
Units for which Nomos is requesting a credit and the amount of the restocking
fee retained by Nomos with respect to such Product Unit. In the event no payment
is owed to WARF, a statement setting forth that fact shall be supplied to WARF.

         Section 4.        Warranties.

                  A.       CERTAIN WARRANTIES OF WARF.

                           (i)      WARF warrants that except as otherwise
provided under Section 14 of this Agreement with respect to U.S. Government
interests, it is the owner of the Licensed Patents and has the right to enter
into this Agreement. However, nothing in this Agreement shall be construed as:

                                    (1)     a warranty or representation by
WARF as to the validity or scope of any of Licensed Patents;

                                    (2)     a warranty or representation that
anything made, used, sold or otherwise disposed of under the license granted in
this Agreement will or will not infringe patents of third parties;

                                    (3)     except as otherwise expressly
provided in Section 10, an obligation to bring or prosecute actions or suits
against third parties for infringement of Licensed Patents;

                                    (4)     an obligation to furnish any
know-how not provided in Licensed Patents; or

                                    (5)     a warranty or representation by
WARF that it will not grant licenses to others to make, use or sell products not
covered by the claims of the Licensed Patents which may be similar and/or
compete with Products made or sold by Nomos.

                           (ii)     WARF MAKES NO REPRESENTATIONS, EXTENDS NO
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO
RESPONSIBILITIES WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER DISPOSITION BY
NOMOS OR ITS VENDEES OR OTHER TRANSFEREES OF PRODUCTS INCORPORATING OR MADE BY
USE OF INVENTIONS LICENSED UNDER THIS AGREEMENT.

                  B.       CERTAIN WARRANTIES AND RESPONSIBILITIES OF NOMOS.

                                      -4-
<PAGE>

                  Nomos warrants that it has, or will obtain, the expertise
necessary to independently evaluate the inventions of the Licensed Patents. All
development activities and strategies and all aspects of Products design and
decisions to market and the like are entirely at the discretion of Nomos, and
Nomos shall rely entirely on its own expertise with respect thereto.

         Section 5.        RECORDKEEPING.

                  A. Nomos shall keep books and records sufficient to verify the
accuracy and completeness of Nomos's accounting referred to above. Such books
and records shall be preserved for a period not less than six years after they
are created during and after the term of this Agreement.

                  B. Nomos shall take all steps necessary so that WARF may
within thirty days of its request review and copy all the books and records at a
single U.S. location to verify the accuracy of Nomos's accounting. Such review
may be performed by any licensing or accounting employee of WARF as well as by
any attorney or registered CPA designated by WARF, upon reasonable notice and
during regular business hours.

                  C. If a royalty payment deficiency is determined, Nomos shall
pay the royalty deficiency outstanding within thirty (30) days of receiving
written notice thereof, plus interest on outstanding amounts as described in
Section 3E(i).

                  D. If a royalty payment deficiency for a calendar year exceeds
five percent (51) of the royalties paid for that year, then Nomos shall be
responsible for paying WARF's out-of-pocket expenses incurred with respect to
such review.

         Section 6.        TERM; TERMINATION.

                  A. The term of this license shall begin on the effective date
of this Agreement and continue until the earlier of the date that no Licensed
Patent remains an enforceable patent or the payment of earned royalties under
Section 3C, once begun, ceases for more than four (4) calendar quarters.

                  B.       Nomos may terminate this Agreement at any time by
giving at least ninety days' written and unambiguous notice of such termination
to WARF. Such a notice shall be accompanied by a statement of the reasons for
termination.

                  C. If Nomos at any time defaults in the timely payment of any
monies due to WARF or commits any breach of any other covenant herein contained,
and Nomos fails to remedy any such breach or default within ninety days after
written notice thereof by WARF, WARF may, at its option, terminate this
Agreement by giving notice of termination to Nomos.

                  D. Upon the termination of this Agreement, Nomos shall remain
obligated to provide an accounting for and to pay royalties earned up to the
date of the termination and any minimum royalties shall be prorated as of the
date of termination by the number of days elapsed

                                      -5-
<PAGE>

in the applicable calendar year. The provisions of Sections 2B and 8 of this
Agreement, and Sections 2A(i)(2) and 2A(ii)(2) to the extent all applicable
royalties have been paid by Nomos with respect to the Products used pursuant to
such sections, shall survive the termination of this Agreement.

         Section 7         ASSIGNABILITY.

         This Agreement may not be transferred or assigned by Nomos except with
the prior written consent of WARF, which consent shall not be unreasonably
withheld. If WARF consents to a transfer or assignment, the royalty rate for
Products leased or sold in the Add-On-Device Field shall be increased to $[* *
*] per Product Unit (plus $[* * *] for Verification Product Units) and the [* *
*] royalty reduction specified in Section 3C shall thereafter be void.

         Section 8.        ASSIGNMENT OF CERTAIN CLAIMS.

         In consideration for the license grants make herein, Nomos hereby
agrees to assign and transfer to WARF complete title and right to any patent
claims which would, if allowed, result in the declaration of an interference
with any claim issued or pending now, or any claim pending or issued in the
future, contained in any Licensed Patent. Should Nomos become aware of any
potentially interfering claim or claims, or any right to prosecute an
interfering claim or claims, then Nomos shall inform WARF of such claims or
rights to claims, after which such claim or claims shall, under the provisions
of this paragraph, become the property of WARF. Nomos shall also freely supply
to WARF any and all information and copies of records reasonably requested by
WARF or its counsel, which information or records are necessary and relevant to
a determination of the dates of invention by any named inventors in any Nomos
patent application. Nomos and WARF shall confer regarding such information or
records and their respective opinions as to dates of invention by the respective
inventors. If WARF should determine, after due investigation and due
consideration of Nomos's information and opinions, that one or more Nomos
inventors can establish earlier dates of invention than previously named
inventors who have assigned to WARF, then WARF shall take such action as
appropriate to prosecute its patent rights and/or to correct its patents so as
to name such a Nomos inventor as an inventor on a WARF patent or patent
application. Nomos agrees to execute, and to require any inventors named on its
patent applications to execute, any declarations of fact or documents of title
necessary to accomplish the objectives of this paragraph.

         Section 9.        CONTEST OF VALIDITY.

         In the event Nomos contests the validity of any Licensed Patent, Nomos
shall continue to pay royalties with respect to that patent as if such contest
were not underway until the patent is adjudicated invalid or unenforceable by a
court of last resort.

         Section 10.       ENFORCEMENT.

--------------------

* * * Confidential material redacted and filed separately with the Commission.

                                      -6-

<PAGE>

                  A. WARF intends to protect Licensed Patents against infringers
or otherwise act to eliminate infringement, when, in WARF's sole judgment, such
action may be reasonably necessary, proper, and justified, and any enforcement
proceedings shall be under WARF's sole control. In the event that Nomos believes
there is infringement of any Licensed Patent under this Agreement which is to
Nomos's substantial detriment, Nomos shall provide WARF with notification and
reasonable evidence of such infringement.

                  B. If, during the period that the license granted in Section
2A(ii) remains exclusive, the infringement of a Licensed Patent in the United
States is to Nomos's substantial detriment for a Product licensed to Nomos in
the Add-On-Device Field hereunder and such infringement has continued for six
months after Nomos has provided WARF with:

                           (i)      a written request that WARF take action to
                                    abate or terminate such infringement,

                           (ii)     reasonable evidence of the infringement, and

                           (iii)    a clear opinion, by an outside patent
                                    counsel acceptable to WARF, that is
                                    addressed to WARF and that unconditionally
                                    states that the complained of activity is an
                                    infringement and that enforcement of the
                                    Licensed Patent will not constitute patent
                                    misuse or abuse,

then WARF shall notify Nomos that WARF will, at its sole option, either:

                           (i)      bring an infringement action in WARF's own
                                    name, in which case WARF shall be
                                    responsible for all expenses incurred with
                                    respect thereto (including attorneys fees)
                                    and WARF shall be entitled to any damages
                                    recovered therein;

                           (ii)     bring an infringement action jointly
                                    with Nomos, in which case Nomos and WARF
                                    shall be each be responsible for paying
                                    fifty percent (50%) of the expenses
                                    incurred with respect thereto (including
                                    attorneys fees), Nomos and WARF shall
                                    each be entitled to a share of fifty
                                    percent (50%) of the aggregate damages
                                    recovered therein, and WARF shall
                                    control the prosecution of such action
                                    (provided Nomos shall have the right to
                                    consult with WARF regarding major
                                    decisions arising in the action and WARF
                                    shall give due consideration to Nomos's
                                    opinions with respect thereto); or

                           (iii)    permit Nomos to bring an infringement
                                    action, in which case Nomos shall have
                                    right to file a lawsuit to seek to stop
                                    such activity at its own expense and be
                                    entitled to any damages covered therein
                                    (with royalties payable to WARF under
                                    Section 3C based on the number of
                                    Product Units sold or leased by the
                                    infringer for

                                      -7-

<PAGE>

                                    which Nomos obtained damages); provided
                                    that during such litigation Nomos shall
                                    act in good faith to preserve WARF's
                                    right, title and interest in and to the
                                    Licensed Patent, shall keep WARF advised
                                    as to the status of the litigation and
                                    shall not enter into a settlement of
                                    such litigation without first allowing
                                    WARF the option of either approving the
                                    settlement or of continuing the
                                    litigation at WARF's expense for WARF's
                                    benefit (upon payment to Nomos of its
                                    out-of-pocket costs and expenses,
                                    including attorneys fees, incurred in
                                    the litigation).

If WARF has elected to bring an infringement action in WARF's own name pursuant
to clause (i) above, Nomos may elect to require such that action be brought
jointly with Nomos as provided in clause (ii) by notifying WARF of Nomos's
election in writing within thirty (30) days after receiving notice from WARF of
WARF's election. Nothing herein shall permit or allow Nomos to commence any
action for infringement of the Licensed Patent for any activity allowed under a
settlement arrangement entered into by WARF in good faith with a third party
infringer.

         Section 11.       PATENT MARKING.

         Nomos shall insure that it applies patent markings that meet all
requirements of U.S. law, 35 U.S.C. 287, with respect to all Products subject to
this Agreement. An example of an acceptable label is "Covered by one or more of
the following patents: [list all applicable patent numbers]."

         Section 12.       PRODUCT LIABILITY; CONDUCT OF BUSINESS.

                  A. Nomos shall, at all times during the term of this Agreement
and thereafter, indemnify, defend and hold WARF and the inventors of the
Licensed Patents harmless against all claims and expenses, including legal
expenses and reasonable attorneys fees, arising out of the death of or injury to
any person or persons or out of any damage to property and against any other
claim, proceeding, demand, expense and liability of any kind whatsoever (other
than patent infringement claims) resulting from the production, manufacture,
sale, use, lease, consumption or advertisement of Products arising from any
right or obligation of Nomos hereunder. Notwithstanding the above, WARF at all
times reserves the right to retain counsel of its own, at WARF's expense, to
defend WARF's interests.

                  B. Nomos warrants that it now maintains and will continue to
maintain liability insurance coverage appropriate to the risk involved in
marketing the products subject to this Agreement and that such insurance
coverage lists WARF and the inventors of the Licensed Patents as additional
insureds. Within ninety (90) days after the execution of this Agreement and
thereafter annually between January 1 and January 31 of each year, Nomos will
present evidence to WARF that the coverage is being maintained with WARF and its
inventors listed as additional insureds. In addition, Nomos shall provide WARF
with at least 30 days prior written notice of any change in or cancellation of
the insurance coverage.

                                      -8-
<PAGE>

                  C. If WARF grants any third party a sublicense under the Nomos
Patents, and WARF's agreement with such third party requires the third party to
indemnify, defend, or obtain insurance protecting WARF from claims relating to
the patents licensed under such agreement, then such agreement shall also
require the third party to indemnify, defend and obtain insurance protecting
Nomos and Mark Carol to the same extent that such party has agreed to indemnify,
defend and obtain insurance protecting WARF. However, WARF shall not be
responsible for the actions or obligations of any such third party, WARF shall
not be obligated to monitor or enforce such obligations in the agreement, and
WARF shall have no obligation to indemnify, defend or obtain insurance
protecting Nomos or Mark Carol or any other party from any actions or claims
whatsoever.

                  D. If WARF grants any third party a license under any
WARF-owned patents in which Mark Carol is a named inventor, and WARF's agreement
with such third party requires the third party to indemnify, defend, or obtain
insurance protecting WARF's inventors from claims relating to the patents
licensed under such agreement, then such agreement shall also require the third
party to indemnify, defend and obtain insurance protecting Mark Carol to the
same extent that such party has agreed to indemnify, defend and obtain insurance
protecting WARF's inventors. However, WARF shall not be responsible for the
actions or obligations of any such third party, WARF shall not be obligated to
monitor or enforce such obligations in the agreement, and WARF shall have no
obligation to indemnify, defend or obtain insurance protecting Mark Carol or any
other party from any actions or claims whatsoever.

         Section 13.       USE OF NAMES.

         Except as required under Section 11, Nomos shall not use WARF's name,
the name of any inventor of inventions governed by this Agreement, or the name
of the University of Wisconsin in sales promotion, advertising, or any other
form of publicity without the prior written approval of the entity or person
whose name is being used.

         Section 14.       UNITED STATES GOVERNMENT INTERESTS.

         It is understood that if the United States Government (through any of
its agencies or otherwise) has funded research, during the course of or under
which any of the inventions of the Licensed Patents were conceived or made, the
United States Government is entitled, as a right, under the provisions of 35
U.S.C. ss. 200-212 and applicable regulations of Chapter 37 of the Code of
Federal Regulations, to a nonexclusive, nontransferable, irrevocable, paid-up
license to practice or have practiced the invention of such Licensed Patents for
governmental purposes. Any license granted to Nomos in this Agreement shall be
subject to such right.

         Section 15.       MISCELLANEOUS.

         This Agreement shall be construed in accordance with the internal laws
of the State of Wisconsin. If any provisions of this Agreement are or shall come
into conflict with the laws or regulations of any jurisdiction or any
governmental entity having jurisdiction over the parties or this Agreement,
those provisions shall be deemed automatically deleted, if such deletion is
allowed by relevant law, and the remaining terms and conditions of this
Agreement shall remain

                                      -9-

<PAGE>

in full force and effect. If such a deletion is not so allowed or if such a
deletion leaves terms thereby made clearly illogical or inappropriate in effect,
the parties agree to substitute new terms as similar in effect to the present
terms of this Agreement as may be allowed under the applicable laws and
regulations. The parties hereto are independent contractors and not joint
venturers or partners.

         Section 16.       NOTICES.

         Any notice required to be given pursuant to the provisions of this
Agreement shall be in writing and shall be deemed to have been given at the
earlier of the time when actually received as a consequence of any effective
method of delivery, including but not limited to hand delivery, transmission by
facsimile, or delivery by a professional courier service or the time when sent
by certified or registered mail addressed to the party for whom intended at the
address below or at such changed address as the party shall have specified by
written notice, provided that any notice of change of address shall be effective
only upon actual receipt.

                   (a)     Wisconsin Alumni Research Foundation
                           Attn: Managing Director
                           614 Walnut Street
                           Madison, Wisconsin 53705

                   (b)     Nomos Corporation
                           Attn: President
                           2591 Wexford Bayne Road
                           Suite 400
                           Sewickley, PA 15143

         Section 17        INTEGRATION.

         This Agreement constitutes the full understanding between the parties
with reference to the subject matter hereof, and no statements or agreements by
or between the parties, whether orally or in writing, except as provided for
elsewhere in this Section 17, made prior to or at the signing hereof, shall vary
or modify the written terms of this Agreement. Neither party shall claim any
amendment, modification, or release from any provisions of this Agreement by
mutual agreement, acknowledgement, or otherwise, unless such mutual agreement is
in writing, signed by the other party, and specifically states that it is an
amendment to this Agreement.

         Section 18        AUTHORITY.

         The persons signing on behalf of WARF and Nomos hereby warrant and
represent that they have authority to execute this Agreement on behalf of the
party for whom they have signed.

                                      -10-

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement on the dates indicated below.

WISCONSIN ALUMNI RESEARCH FOUNDATION

By: /s/ Richard H. Leazer
   ------------------------------------
   Richard H. Leazer, Managing Director        Date:  June 19, 1995
                                                    ---------------

NOMOS CORPORATION

By: /s/ Mark Carol                             Date:  6/5, 1995
    -----------------------------------             ---------------
    Mark Carol, M.D. President

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Reviewed by WARF's Attorney:                Reviewed by Nomos's Attorney:

/s/ [Illegible]                             /s/ Ben D. Tobor
---------------------------------------    ------------------------------------

                        June 1, 1995                              6/9,95
                      --------------------                 --------------------

(Neither attorney shall be deemed a signatory to this Agreement.)

                                      -11-

<PAGE>

                                   APPENDIX A

         A. "Licensed Patents" shall refer to and mean those patents and patent
applications listed on Appendix B hereto that are in countries in the Licensed
Territory and any subsequent patent application owned by WARF in a country in
the Licensed Territory but only to the extent it claims an invention claimed in
a patent application listed on Appendix B in such country.

         B. "Verification Patents" shall refer to and mean U.S. Patent No.
5,394,452 and any foreign Licensed Patent, but only to the extent such foreign
Licensed Patent claims an invention equivalent to the invention claimed in U.S.
Patent No. 5,394,452.

         C. "Nomos Patents" shall refer to and mean U.S. Patent Application
Serial No. 08/284,279, currently entitled "Method and Apparatus for Conformal
Radiation Therapy," any foreign equivalents thereof, and any subsequent patent
application owned by Nomos but only to the extent: (i) it claims an invention
claimed in such U.S. or foreign patent applications; (ii) it is not limited to a
non-slice-by-slice radiation therapy apparatus; and (iii) it is not limited to a
non-fan beam radiation therapy apparatus.

         D. "Product" shall mean any radiation therapy apparatus that employs or
is in any way produced by the practice of an invention claimed in the Licensed
Patents (whether issued or pending) or that would otherwise constitute
infringement of any claims of the Licensed Patents (whether issued or pending).
The parties agree that "Product" shall include any treatment planning system
software as long as claim 7 of U.S. Patent Application No. 08/191,243 remains
pending (in the original application or any derivative thereof) or has been
issued. If claim 7 is abandoned and the treatment planning system software does
not at any time employ and is not in any way produced by the practice of any
other claim of any Licensed Patent (whether issued or pending) and would not
otherwise constitute infringement of any Licensed Patent (whether issued or
pending), then such software shall not thereafter constitute a Product
hereunder.

         E. "Verification Product" shall mean any Product that employs or is in
any way produced by the practice of an invention claimed in the Verification
Patents (whether issued or pending), except claim #6 of the U.S. Verification
Patent and the equivalent claim(s) in any foreign application, or any Product
that would otherwise constitute infringement of any claims of the Verification
Patents (whether issued or pending), except claim #6 of the U.S. Verification
Patent and the equivalent claim(s) in any foreign application.

         F. "Unit" shall mean any single radiation therapy apparatus or item of
software, regardless of whether such apparatus or item of software is packaged
with other radiation therapy apparatuses, software or any other products.

         G. "Medical Imaging Field" shall be limited to the field of medical
imaging devices.

         H. "Add-On Device Field" shall be limited to the field of the
manufacture of Products solely as an Add-On Accessory to a Constrained Rotation
Linear Accelerator made by a third party who is neither the Add-On

                                      -12-
<PAGE>

Accessory manufacturer nor an Affiliate of the Add-On Accessory manufacturer,
where the combined device is intended for use only in the Medical Imaging Field.

         I. "Add-On Accessory" shall mean any add-on accessory or software
(including without limitation the treatment planning system software) designed
to operate in conjunction with a Constrained Rotation Linear Accelerator, except
that the term "Add-On Accessory" shall not include either the linear accelerator
itself or any Beam Directing Device.

         J. "Beam Directing Device" shall mean any gantry or other device or
method for directing or redirecting the beam from a linear accelerator or
otherwise changing the angle of such a beam.

         K. "Constrained Rotation Linear Accelerator" shall mean any linear
accelerator in combination with a Beam Directing Device in which the output beam
cannot be rotated more than 360 degrees in a single direction of arc.

         L. "Affiliate of the Add-On Accessory Manufacturer" shall mean:

            (i) any person or entity directly or indirectly owning or
controlling at least twenty percent (20%) of the equity interest normally
entitled to vote for election of the management of the Add-On Accessory
Manufacturer; and

            (ii) any entity in which either the Add-on Accessory Manufacturer
or a person or entity described in subparagraph W directly or indirectly owns or
controls at least fifty percent (50%) of the equity interest normally entitled
to vote for election of the management of such entity.

         M. "Licensed Territory" shall be worldwide.

                                      -13-

<PAGE>

                                   APPENDIX B

                    LICENSED PATENTS AND PATENT APPLICATIONS

<TABLE>
<CAPTION>

REFERENCE NUMBER           COUNTRY                PATENT NUMBER          ISSUE DATE              SERIAL NUMBER
-----------------------------------------------------------------------------------------------------------------
<S>                       <C>                             <C>            <C>                   <C>
METHOD AND APPARATUS FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES)

P91009US                  U.S.                            5,317,616      5/31/94
P91009AU                  Australia                                                                   35323/93
P91009CA                  Canada                                                                       2091275
P91009EP                  EPO                                                                       93301672.7
P91009IL                  Israel                                                                        104896
P91009JP                  Japan                                                                        5-58983
P91009KR                  South Korea                                                                4146/1993
P91009MX                  Mexico                                                                        931495
P91009NZ                  New Zealand                                                                   247042

MULTI-LEAF RADIATION ATTENUATOR FOR RADIATION THERAPY (SWERDLOFF, MACKIE,
HOLMES)

P92142US                  U.S.                            5,351,280      9/27/94
P92142WO                  PCT                                                                       US94/06487

RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF, MACKIE,
HOLMES)

P92135US                  U.S.                                                                      08/071,742
P92135US                  PCT                                                                       US94/06488

DYNAMIC COLLIMATOR FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES, RECKWERDT)

P92138US                  U.S.                                                                      08/071,741

METHOD AND APPARATUS FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES)

P94001                    U.S.                                                                      08/191,243
</TABLE>

                                      -14-

<PAGE>

<TABLE>
<CAPTION>

REFERENCE NUMBER           COUNTRY                PATENT NUMBER          ISSUE DATE              SERIAL NUMBER
-----------------------------------------------------------------------------------------------------------------
<S>                       <C>                             <C>            <C>                   <C>
RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF, MACKIE,
HOLMES)

P95061                    U.S.                                                                   [To be filed]

VERIFICATION SYSTEM FOR RADIATION THERAPY (SWERDLOFF, MACKIE,
HOLMES)

P92140                    U.S.                            5,394,452                              2/28/95

DYNAMIC BEAM FLATTENING APPARATUS FOR RADIATION THERAPY
(SWERDLOFF, MACKIE, HOLMES)

P92137US                  U.S.                                                                   08/074,192
P92137US                  PCT                                                                    US94/06489
</TABLE>

                                      -15-<PAGE>
                                                                Exhibit 10.18(a)

                            PATENT LICENSE AGREEMENT

THIS Agreement is between the Board of Regents ("Board") of The University of
Texas System ("System"), an agency of the State of Texas, whose address is 201
West 7th Street, Austin, Texas 78701, and NOMOS CORPORATION, a Delaware
corporation having a principal place of business located at 2591 Wexford Bayne
Road, Sewickley, PA 15143 ("Licensee"). Board and Licensee shall be hereinafter
referred to collectively as the "Parties" and individually as the "Party."

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>

<S>      <C>                                                                                    <C>
         RECITALS                                                                                2

1.       EFFECTIVE DATE                                                                          2

2.       DEFINITIONS                                                                             2

3.       WARRANTY, SUPERIOR RIGHTS                                                               3

4.       LICENSE                                                                                 4

5.       PAYMENTS AND REPORTS                                                                    5

6.       TERM AND TERMINATION                                                                    7

7.       INFRINGEMENT BY THIRD PARTIES                                                           9

8.       ASSIGNMENT                                                                              9

9.       PATENT MARKING                                                                          9

10.      INDEMNIFICATION                                                                         9

11.      USE OF BOARD AND COMPONENT'S NAME                                                       10

12.      CONFIDENTIAL INFORMATION                                                                10

13.      PATENTS AND INVENTORS                                                                   11

14.      ALTERNATE DISPUTE RESOLUTION                                                            11

15.      GENERAL                                                                                 12

         SIGNATURES                                                                              14
</TABLE>

<PAGE>

                                                                  EXECUTION COPY

                                    RECITALS

A. Board owns certain Patent Rights and Technology Rights related to Licensed
Subject Matter, which were developed at The University of Texas Health Science
Center at San Antonio ("University"), a component institution of System.

B. Board desires to have the Licensed Subject Matter developed and used for the
benefit of Licensee, Inventor, Board, and the public as outlined in Board's
Intellectual Property Policy.

C. Licensee wishes to obtain a license from Board to practice Licensed Subject
Matter.

         NOW, THEREFORE, in consideration of the mutual covenants and premises
herein contained, the parties agree as follows:

1. EFFECTIVE DATE

This Agreement is effective October 21, 1998 ("Effective Date").

2. DEFINITIONS

As used in this Agreement, the following terms have the meanings indicated:

         2.1 "Affiliate" means any business entity more than 50% owned by
Licensee, any business entity which owns more than 50% of Licensee, or any
business entity that is more than 50% owned by a business entity that owns more
than 50% of Licensee.

         2.2 "Licensed Field" means all radiation therapy applications deriving
from the Patent Rights or Technology Rights.

         2.3 "Licensed Product" means any product Sold by Licensee comprising
Licensed Subject Matter pursuant to this Agreement.

         2.4 "Licensed Subject Matter" means inventions and discoveries covered
by Patent Rights or Technology Rights within Licensed Field.

         2.5      "Licensed Territory" means world-wide.

                                       2
<PAGE>

                                                                  EXECUTION COPY

         2.6 "Net Sales" means the gross revenues received by Licensee from the
Sale of Licensed Products less sales and/or use taxes actually paid, import
and/or export duties actually paid, outbound transportation prepaid or allowed,
and amounts allowed or credited due to returns (not to exceed the original
billing or invoice amount).

         2.7 "Patent Rights" means Board's rights in information or discoveries
covered by United States Patent Application filed on October 21, 1998 entitled
"Couch Mounted Tomotherapy Treatment Device and Methods of Using the Same" by
Bill J. Salter ("Inventor") and all divisions, continuations,
continuations-in-part, reissues, reexaminations or extensions thereof, and any
letters patent that issue thereon, whether domestic or foreign.

         2.8 "Peacock(R) System" means a system for the delivery of intensity
modulated radiation therapy comprising the CORVUS Inverse Treatment Planning
System (or its functional equivalent) and/or the MIMiC Multileaf Collimator (or
its functional equivalent), as they may be modified from time to time.

         2.9 "Sale or Sold" means the transfer or disposition of a Licensed
Product for value to a party other than Licensee.

         2.10 "Technology Rights" means Board's rights in technical information,
know-how, processes, procedures, compositions, devices, methods, formulas,
protocols, techniques, software, designs, drawings or data created by Inventor
at University before or after the Effective Date relating to apparatus and
methods for delivering radiation therapy which are not covered by Patent Rights,
but which are necessary for practicing the invention covered by Patent Rights.

3. WARRANTY: SUPERIOR-RIGHTS

         3.1 Except for the rights, if any, of the Government of the United
States, as set forth below, Board represents and warrants its belief to the best
of its knowledge, after due inquiry, that (i) it is the owner of the entire
right, title, and interest in and to Licensed Subject Matter, (ii) it has the
sole right to grant licenses thereunder, and (iii) it has not knowingly granted
licenses thereunder to any other entity that would restrict rights granted to
Licensee except as stated herein.

         3.2 Licensee understands that the Licensed Subject Matter may have been
developed under a funding agreement with the Government of the United States of
America (the "Government") and, if so, that the Government may have certain
rights relative thereto. This Agreement is explicitly made subject to the
Government's rights under any agreement and any applicable law or regulation. If

                                       3
<PAGE>

                                                                  EXECUTION COPY

there is a conflict between an agreement, applicable law or regulation and this
Agreement, the terms of the Government agreement, applicable law or regulation
shall prevail. The Board shall be responsible for any payments or fees of any
kind payable to the Government of the United States under any such agreement,
law or regulation. To the best of Board's knowledge, this Agreement does not
conflict with or require the approval of the Government.

         3.3 Licensee understands and acknowledges that Board, by this
Agreement, makes no representation as to the operability or fitness for any use,
safety, efficacy, ability to obtain regulatory approval, patentability, and/or
breadth of the Licensed Subject Matter. Board, by this Agreement, also makes no
representation as to whether there are any patents now held, or which will be
held, by others or by Board in the Licensed Field, nor does Board make any
representation that the inventions contained in Patent Rights do not infringe
any other patents now held or that will be held by others or by Board.

         3.4 Licensee, by execution hereof, acknowledges, covenants, and agrees
that it has not been induced in any way by Board, System, University or its
employees to enter into this Agreement, and further warrants and represents
that: (i) it has conducted sufficient due diligence with respect to all items
and issues pertaining to this Article 3 and all other matters pertaining to this
Agreement; and (ii) Licensee has adequate knowledge and expertise, or has
utilized knowledgeable and expert consultants, to adequately conduct the due
diligence, and agrees to accept all risks inherent herein.

4. LICENSE

         4.1 Board hereby grants to Licensee a royalty-bearing, exclusive
license under Licensed Subject Matter to manufacture, have manufactured, import,
offer to sell, and/or sell Licensed Products within the Licensed Territory for
use within Licensed Field. This grant is subject to the payment by Licensee to
Board of all consideration as provided herein, and is further subject to rights
retained by Board to:

          a. Publish the general scientific findings from research related to
          Licensed Subject Matter subject to the terms of Article 12,
          Confidential Information; and

          b. Use Licensed Subject Matter for research, teaching, and other
          educationally-related purposes.

         4.2 Licensee may extend the license granted herein to any Affiliate if
the Affiliate consents to be bound by this Agreement to the same extent as
Licensee.

                                       4
<PAGE>

                                                                  EXECUTION COPY

         4.3 Licensee may grant sublicenses consistent with this Agreement if
Licensee is responsible for the operations of its sublicensees relevant to this
Agreement as if the operations were carried out by Licensee, including the
payment of royalties whether or not paid to Licensee by a sublicensee. Licensee
must deliver to Board a true and correct copy of each sublicense granted by
Licensee, and any modification or termination thereof, within 30 days after
execution, modification, or termination. When this Agreement is terminated, all
existing sublicenses granted by Licensee must terminate as well. This
termination right does not apply to products previously sold to third parties
for use in the Peacock(R) System.

5. PAYMENTS AND REPORTS

         5.1 In consideration of rights granted by Board to Licensee under this
Agreement, Licensee will pay Board the following:

               (a.) a non-refundable license documentation fee in the amount of
               $25,000 due and payable when this Agreement is executed by
               Licensee;

               (b.) a royalty of $4,000 for the Sale, in conjunction with the
               Sale of a Peacock(R) System, of a Licensed Product capable of
               translating a radiation therapy treatment couch solely via manual
               operation (i.e., the motive force for translation is supplied via
               direct physical manipulation of the Licensed Product by an
               operator thereof) ("Manual Licensed Product");

               (c.) a royalty of $5,000 for the Sale, in conjunction with the
               Sale of a Peacock(R) System, of a Licensed Product capable of
               translating a radiation therapy treatment couch by means other
               than or in addition to manual operation ("Self-motive Licensed
               Product");

               (d.) a running royalty equal to 20% of Net Sales or a royalty of
               $4,000, whichever is greater, for each Manual Licensed Products
               Sold independently from the Sale of a Peacock(R) System and
               covered by Patent Rights or Technology Rights;

               (e.) a running royalty equal to 15% of Net Sales or a royalty of
               $5,000, whichever is greater, for each Self-motive Licensed
               Product Sold independently from the Sale of a Peacock(R) System
               and covered by Patent Rights or Technology Rights; and

                                       5
<PAGE>

                                                                  EXECUTION COPY

               (f.) minimum yearly royalties of $100,000 due within 30 days of
               the first anniversary, $125,000 due within 30 days of the second
               anniversary, and $125,000 due within 30 days of the third
               anniversary of the first Sale of a Licensed Product.

         5.2 During the Term of this Agreement and for 1 year thereafter,
Licensee agrees to keep complete and accurate records of its and its
sublicensees' Sales and Net Sales of Licensed Products under the license granted
in this Agreement in sufficient detail to enable the royalties payable hereunder
to be determined. Licensee agrees to permit Board or its representatives, at
Board's expense, to periodically examine its books, ledgers, and records during
regular business hours for the purpose of and to the extent necessary to verify
any report required under this Agreement, but not more than twice in any
calendar year. If the amounts due to Board are determined to have been underpaid
by more than five (5%) percent of the correct amount due, Licensee will pay the
cost of the examination and accrued interest at the rate of twelve (12%) percent
per annum.

         5.3 Within 30 days after March 31, June 30, September 30, and December
31, beginning immediately after the Effective Date, Licensee must deliver to
Board a true and accurate written report, even if no payments are due Board,
giving the particulars of the business conducted by Licensee and its
sublicensee(s), if any exist, during the preceding 3 calendar months under this
Agreement as are pertinent to calculating payments hereunder. This report will
include at least:

               a. the quantities of Licensed Subject Matter that it has
               produced;

               b. the total Sales;

               c. the calculation of royalties thereon; and

               d. the total royalties computed and due Board.

Simultaneously with the delivery of each report, Licensee must pay to Board the
amount, if any, due for the period of each report.

         5.4 On or before each anniversary of the Effective Date, irrespective
of having a first Sale or offer for Sale, Licensee must deliver to Board a
written progress report as to Licensee's (and any sublicensee's) efforts and
accomplishments during the preceding year in diligently commercializing Licensed
Subject Matter in the Licensed Territory and Licensee's (and, if applicable,
sublicensee's) commercialization plans for the upcoming year.

                                       6
<PAGE>

                                                                  EXECUTION COPY

         5.5 All amounts payable here by Licensee must be paid in United States
funds without deductions for taxes, assessments, fees, or charges of any kind,
except as required by applicable law. Checks must be payable to Board of
Regents, The University of Texas System, and shall be delivered to:

R. B. Price
Executive Vice President for
Administration and Business Affairs
The University of Texas
Health Science Center at San Antonio
San Antonio, Texas 78284-7862

         5.6 Upon receiving a first notice of allowance for a patent application
covered under Paragraph 2.7 (Patent Rights), Licensee must reimburse Board for
all its out-of-pocket expenses thus far incurred in filing, prosecuting,
enforcing and maintaining exclusively licensed Patent Rights , up to a maximum
reimbursement of $10,000 during the Term. Notwithstanding the $10,000 maximum
reimbursement during the Term, if the Term is extended pursuant to Paragraph
6.1, Licensee agrees to reimburse Board for all its Patent Costs incurred prior
to the effective date of the extension, up to a maximum reimbursement of
$15,000.

6. TERM AND TERMINATION

         6.1 The term of this Agreement is from the Effective Date until the
third anniversary thereof ("Term"). The Term may be extended for additional
periods of 2 years by mutual agreement of the Parties. However, the Term shall
not exceed the term or terms of any patents covered by Patent Rights.

         6.2 Any time after 1 year from the Effective Date, Board and University
have the right to terminate the exclusivity of this license in any national
political jurisdiction in the Licensed Territory if Licensee, within 90 days
after receiving written notice from University of intended termination of
exclusivity, fails to provide written evidence reasonably satisfactory to
University that Licensee or its sublicensee has commercialized or is actively
attempting to commercialize a licensed invention in such jurisdiction(s).

         6.3 Any time after 2 years from the Effective Date, Board and
University have the right to terminate this license in any national political
jurisdiction in the Licensed Territory if Licensee, within 90 days after
receiving written notice from University of intended termination, fails to
provide written evidence reasonably satisfactory to University that Licensee or
its sublicensee has commercialized or is actively attempting to commercialize a
licensed invention in such jurisdiction(s).

                                       7
<PAGE>

                                                                  EXECUTION COPY

         6.4 The following definitions apply to Article 6: (i) "Commercialize"
means having Sales of Licensed Products in such jurisdiction; and (ii) "Active
attempts to commercialize" means having Sales of Licensed Products or an
effective, ongoing and active research, development, manufacturing, marketing or
sales program as commercially appropriate, directed toward obtaining regulatory
approval, production or Sales of Licensed Products in any jurisdiction, and
plans acceptable to University, in its sole discretion, to commercialize
licensed inventions in the jurisdiction(s) that University intends to terminate.

         6.5. Licensee agrees to develop a vigorous sublicensing program to
effect commercialization of Licensed Subject Matter in any portion of the
Licensed Field that Licensee does not exploit.

         6.6. This Agreement will earlier terminate:

               a. automatically if Licensee becomes bankrupt or insolvent and/or
               if the business of Licensee is placed in the hands of a receiver,
               assignee, or trustee, whether by voluntary act of Licensee or
               otherwise; or

               b. upon 30 days written notice from Board if Licensee breaches or
               defaults on its obligation to make payments (if any are due) or
               reports, in accordance with the terms of Article 5, unless,
               before the end of the 30 day period, Licensee has cured the
               default or breach and so notifies Board, stating the manner of
               the cure; or

               c. upon 90 days written notice if Licensee breaches or defaults
               on any other obligation under this Agreement, unless, before the
               end of the 90 day period, Licensee has cured the default or
               breach or is acting diligently to make such cure, and so notifies
               Board, stating the manner of the cure; or

               d. at any time by mutual written agreement between Licensee,
               University, and Board, upon 180 days written notice to all
               parties listed in Paragraph 15.2 and subject to any terms herein
               which survive termination; or

               e. under the provisions of Paragraphs 6.2 and 6.3 if invoked.

         6.7. If this Agreement is terminated for any cause:

               a. nothing herein will be construed to release either Party of
               any obligation matured prior to the effective date of the
               termination;

                                       8
<PAGE>

                                                                  EXECUTION COPY

               b. after the effective date of the termination, Licensee may sell
               all Licensed Products and parts therefor it has on hand at the
               date of termination, if it pays earned royalties thereon
               according to the terms of Article 5; and

               c. Licensee will be bound by the provisions of Articles 10
               (Indemnification), 11 (Use of Board and Component's Name), and 12
               (Confidential Information) of this Agreement.

7. INFRINGEMENT BY THIRD PARTIES

         7.1 Licensee, at its expense, must enforce any patent exclusively
licensed hereunder against infringement by third parties and it is entitled to
retain recovery from such enforcement. Licensee must pay Board a royalty on any
monetary recovery if the monetary recovery is for damages or a reasonable
royalty in lieu thereof. If Licensee does not file suit against a substantial
infringer of a patent within 6 months of knowledge thereof, then Board may
enforce any patent licensed hereunder on behalf of itself and Licensee, Board
retaining all recoveries from such enforcement and/or reducing the license
granted hereunder to non-exclusive.

         7.2 In any infringement suit or dispute, the Parties agree to cooperate
fully with each other. At the request and expense of the Party bringing suit,
the other Party will permit access to all relevant personnel, records, papers,
information, samples, specimens, etc., during regular business hours.

8. ASSIGNMENT

         Except in connection with the sale of substantially all of Licensee's
assets to a third party, this Agreement may not be assigned by Licensee without
the prior written consent of Board, which will not be unreasonably withheld.

9. PATENT MARKING

         Licensee must permanently and legibly mark all products and
documentation manufactured or sold by it under this Agreement with a patent
notice as may be permitted or required under Title 35, United States Code.

10. INDEMNIFICATION

         Subject to the terms of this Agreement, Licensee agrees to hold
harmless and indemnify Board, System, University, its Regents, officers,
employees and agents from and against any claims, demands, or causes of action
whatsoever, including without limitation those arising on account of any injury
or death of persons or

                                       9

<PAGE>

                                                                  EXECUTION COPY

damage to property caused by, or arising out of, or resulting from, the exercise
or practice of the license granted hereunder by Licensee, its Affiliates, or
their officers, employees, agents, or representatives, except for liabilities
resulting from the indemnified parties' gross negligence or willful acts or
omissions.

         Subject to the terms of this Agreement, the Board and System agree, to
the extent authorized under the Constitution and laws of the State of Texas, to
hold harmless and indemnify Licensee, its officers, employees and agents from
liability resulting from the negligent acts or omissions of Board, System,
University, its Regents, officers, employees and agents pertaining to the
activities to be carried out pursuant to the obligations of this Agreement,
except for liabilities resulting from the indemnified parties' negligence or
willful acts or omissions.

11. USE OF BOARD AND COMPONENT'S NAME

         Licensee may not use the name of University, System, or Board without
express written consent.

12. CONFIDENTIAL INFORMATION AND PUBLICATION

         12.1 Board and Licensee each agree that all information contained in
documents marked "confidential" and forwarded to one by the other are to (i) be
received in strict confidence, (ii) be used only for the purposes of this
Agreement, and (iii) not be disclosed by the recipient Party, its agents or
employees without the prior written consent of the other Party, except to the
extent that the recipient Party can establish competent written proof that such
information:

               (a.) was in the public domain at the time of disclosure;

               (b.) later became part of the public domain through no act or
               omission of the recipient Party, its employees, agents,
               successors or assigns;

               (c.) was lawfully disclosed to the recipient Party by a third
               party having the right to disclose it;

               (d.) was already known by the recipient Party at the time of
               disclosure;

               (e.) was independently developed by the recipient Party; or

               (f.) is required by law or regulation to be disclosed.

                                       10
<PAGE>

                                                                  EXECUTION COPY

         12.2 Each Party's obligation of confidence hereunder shall be fulfilled
by using at least the same degree of care with the other Party's confidential
information as it uses to protect its own confidential information. This
obligation shall exist while this Agreement is in force and for a period of 3
years thereafter.

         12.3 University will submit its manuscript for any proposed publication
of research related to Licensed Subject Matter to Licensee at least 30 days
before publication, and Licensee shall have the right to review and comment upon
the publication in order to protect Licensee's confidential information. Upon
Licensee's request, publication will be delayed up to 60 additional days to
enable Licensee to secure adequate intellectual property protection of
Licensee's property that would be affected by the publication.

13. PATENTS AND INVENTIONS

         13.1 If after consultation with Licensee, both Parties agree that a
patent application should be filed for Licensed Subject Matter, Board will
prepare and, after consultation with Licensee, file the appropriate patent
applications, and Licensee will pay the reasonable cost of searching, preparing,
filing, prosecuting, and maintaining same. If Licensee notifies Board that it
does not intend to pay the cost of an application, or if Licensee does not
respond or make an effort to agree with Board on the disposition of rights in
the subject invention, then Board may file an application at its own expense and
Licensee will have no rights to the invention. Board will provide Licensee a
copy of any patent application for which Licensee has paid the cost of filing,
as well as copies of any documents received or filed with the respective patent
office during the prosecution thereof.

14.   ALTERNATE DISPUTE RESOLUTION

         14.1 The Parties agree that any dispute or controversy arising out of
or relating to this Agreement, its construction, or its actual or alleged breach
will be decided by mediation, in accordance with the provisions of TEX. CIV.
PRAC. & REM. Codess.ss.154.001- 154.073 (Vernon 1997) and TEX. GOV'T
Codess.ss.2008.001- 2008.055 (Vernon 1997 & Supp. 1998). If the mediation does
not result in a resolution of such dispute or controversy, it will be decided by
another method of alternate dispute resolution in accordance with the provisions
of TEX. CIV. PRAC. & REM. Codess.ss.154.001- 154.073 (Vernon 1997) and TEX.
GOV'T Codess.ss.2008.001- 2008.055 (Vernon 1997 & Supp. 1998), including without
limitation, arbitration, conducted in the city of San Antonio, Texas in
accordance with the License Agreement Arbitration Rules of the American
Arbitration Association. The arbitration panel will include members
knowledgeable in the commercialization and licensing of medical devices, and
intellectual property law. The decision of the arbitration must be

                                       11
<PAGE>

                                                                  EXECUTION COPY

sanctioned by a court of law having jurisdiction to be binding upon and
enforceable by the Parties. Judgment upon the award rendered may be entered in
the highest court or forum having jurisdiction, state or federal. The provisions
of this Article 14 will not apply to decisions on the validity or enforceability
of patent claims or to any dispute or controversy as to which any treaty or law
prohibits such arbitration.

15. GENERAL

         15.1 This Agreement constitutes the entire and only agreement between
the Parties for Licensed Subject Matter and all other prior negotiations,
representations, agreements, and understandings are superseded hereby. No
agreements altering or supplementing the terms hereof may be made except by a
written document signed by both Parties.

         15.2 Any notice required by this Agreement must be given by prepaid,
first class, certified mail, return receipt requested, addressed in the case of
Board to:

Board of Regents
The University of Texas System
201 West 7th Street
Austin, Texas 78701
ATTENTION: Office of General Counsel
FAX: (512) 499-4523
PHONE: (512) 499-4462

with copies to:

The University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, Texas 78284-7862
ATTENTION: Jack C. Park, Esq.
Executive Director of Legal Affairs and Technology Licensing
FAX: (210) 567-2047
PHONE: (210) 567-2020

or in the case of Licensee to:
NOMOS CORPORATION
2591 Wexford Bayne Road
Sewickley, PA  15143
ATTENTION: Anil Rastogi, President and CEO
FAX: (724) 934-5488
PHONE: (724) 934-8200

                                       12
<PAGE>

                                                                  EXECUTION COPY

or other addresses as may be given from time to time under the terms of this
notice provision.

         15.3 Licensee must comply with all applicable federal, state and local
laws and regulations in connection with its activities pursuant to this
Agreement.

         15.4 This Agreement will be construed and enforced in accordance with
the laws of the United States of America and of the State of Texas.

         15.5 Failure of Board to enforce a right under this Agreement will not
act as a waiver of that right or the ability to later assert that right relative
to the particular situation involved.

         15.6 Headings are included herein for convenience only and shall not be
used to construe this Agreement.

         15.7 If any part of this Agreement is for any reason found to be
unenforceable, all other parts nevertheless remain enforceable.

                                       13

<PAGE>

                                                                  EXECUTION COPY

IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized
representatives to execute this Agreement.

BOARD OF REGENTS OF THE                     NOMOS CORPORATION
UNIVERSITY OF TEXAS SYSTEM

By    /s/  John P. Howe                     By  /s/  Anil Rastogi
  ------------------------------              ----------------------------------
John P. Howe, III, M.D.                     Anil Rastogi
President                                   President and CEO
University of Texas
Health Science Center at San Antonio

Approved as to Form:

By  /s/ Bethlynn Maxwell    21 Oct. '98
   -----------------------------------------
BethLynn Maxwell
Office of General Counsel

Approved as to Content:

By  /s/  R.B. Price
  ------------------------------------------
R.B. Price
Executive Vice President for
Administration and Business Affairs

                                       14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}]]